Mda-7/IL-24和C-myb在弥漫大B细胞淋巴瘤中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2018.04.010

癌变·畸变·突变 ›› 2018, Vol. 30 ›› Issue (4): 297-301.doi: 10.3969/j.issn.1004-616x.2018.04.010

Mda-7/IL-24和C-myb在弥漫大B细胞淋巴瘤中的表达及其临床意义

马鸣¹, 赵日旸², 吴昊², 白函瑜², 张璁², 赵连梅², 杨兴肖³, 刘丽华⁴, 单保恩²

1. 河北医科大学第四医院检验科, 河北石家庄 050011;
2. 河北医科大学第四医院科研中心, 河北石家庄 050011;
3. 河北医科大学第四医院感染管理科, 河北石家庄 050011;
4. 河北医科大学第四医院肿瘤免疫科, 河北石家庄 050011

收稿日期:2017-08-09 修回日期:2018-03-10 出版日期:2018-07-30 发布日期:2018-07-30
通讯作者: 单保恩,E-mail:shanbaoen@163.com E-mail:shanbaoen@163.com
作者简介:马鸣,E-mail:maming19830419@163.com
基金资助:
河北省卫计委指令性课题（20160171）

Clinical significance of Mda-7/IL-24 and C-myb expression in diffuse large B-cell lymphoma

MA Ming¹, ZHAO Riyang², WU Hao², BAI Hanyu², ZHANG Cong², ZHAO Lianmei², YANG Xingxiao³, LIU Lihua⁴, SHAN Baoen²

1. Clinical Laboratory of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
2. Research Centre of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
3. Department of Infection Management of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
4. Tumor Immunotherapy Department of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China

Received:2017-08-09 Revised:2018-03-10 Online:2018-07-30 Published:2018-07-30

摘要/Abstract

摘要： 目的：研究弥漫大B细胞淋巴瘤（DLBCL）中Mda-7/IL-24和C-myb的表达水平及其临床意义。方法：收集72例DLBCL患者的瘤组织及36例正常淋巴结组织；通过半定量逆转录PCR及免疫组化技术分别从mRNA及蛋白水平检测各组织中Mda-7/IL-24与C-myb的表达水平，并对Mda-7/IL-24与C-myb进行相关性分析；收集患者临床资料，分析瘤组织Mda-7/IL-24与C-myb蛋白表达水平与患者年龄、性别、临床分期、是否骨髓浸润、Ecog评分及国际预后指数（IPI）之间的关系；分析瘤组织Mda-7/IL-24与C-myb蛋白表达水平与患者无进展生存期之间的关系。结果：与正常淋巴结组织相比，DLBCL组织中Mda-7/IL-24 mRNA的表达水平明显降低，而C-myb mRNA的表达水平则明显增高（P < 0.01）；72例DLBCL患者瘤组织中Mda-7/IL-24与C-myb mRNA表达水平呈明显负相关（r=-0.43，P < 0.01）；瘤组织低表达Mda-7/IL-24、高表达C-myb的患者其临床分期晚、易骨髓转移、瘤细胞增殖活性强、IPI积分较高，同时患者无进展生存期较短（P均 < 0.05）。结论：DLBCL组织中Mda-7/IL-24与C-myb的表达呈明显负相关，Mda-7/IL-24低表达或C-myb高表达是DLBCL患者临床预后较差的指标。

关键词: Mda-7/IL-24, C-myb, 弥漫大B细胞淋巴瘤, 预后分析

Abstract: OBJECTIVE: This study aimed to investigate the clinical significance in expression of Mda-7/IL-24 and C-myb in diffuse large B-cell lymphoma (DLBCL) tissues. METHODS: Expression of Mda-7/IL-24 and C-myb in 72 tissues from DLBCL patients and 36 from normal lymphonodus tissues were assayed by reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. The relationship of Mda-7/IL-24 and C-myb expression and age,sex,clinical stage,bone marrow infiltration or not,Ecog scores,IPI index and survival was analyzed,and survival curves were prepared. RESULTS: The results show that compared with normal lymphonodus tissues,expression of Mda-7/IL-24 mRNA was higher,whereas expression of C-myb mRNA was lower. The expression of Mda-7/IL-24 mRNA was negatively correlated with C-myb (r=-0.43,P < 0.01). Low expression of Mda-7/IL-24 or high expression of C-myb were positively correlated with malignant grade,bone morrow metastases,IPI scores and shorter survival period (all P < 0.05). CONCLUSION: In summary,there was a negative correlation between Mda-7/IL-24 and C-myb expression in DLBCL tissues. The low expression of Mda-7/IL-24 and high expression of C-myb could be used as predictors for poor clinical conditions and prognosis of DLBCL.

Key words: Mda-7/IL-24, C-myb, diffuse large B-cell lymphoma, prognosis analysis

中图分类号:

R734.2

马鸣, 赵日旸, 吴昊, 白函瑜, 张璁, 赵连梅, 杨兴肖, 刘丽华, 单保恩. Mda-7/IL-24和C-myb在弥漫大B细胞淋巴瘤中的表达及其临床意义[J]. 癌变·畸变·突变, 2018, 30(4): 297-301.

MA Ming, ZHAO Riyang, WU Hao, BAI Hanyu, ZHANG Cong, ZHAO Lianmei, YANG Xingxiao, LIU Lihua, SHAN Baoen. Clinical significance of Mda-7/IL-24 and C-myb expression in diffuse large B-cell lymphoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 297-301.

参考文献

[1] LI J,FU R,YANG L P,et al. miR-21 expression predicts prognosis in diffuse large B cell lymphoma[J]. Int J Clin Exp Pathol,2015,8(11):15019-15024.
[2] KOLUMAN G,WU X,LEE W P,et al. IL-22R ligands IL-20,IL-22,and IL-24 promote wound healing in diabetic db/db mice[J]. PLoS One, 2017,12(1):e0170639.
[3] SEONG R K,CHOI Y K,SHIN O S,et al. MDA7/IL-24 is an anti-viral factor that inhibits influenza virus replication[J]. J Microbiol,2016,54(10):695-700.
[4] CHEN S,WANG Z,DAI X,et al. Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro[J]. Cancer Sci,2013,104(7):826-834.
[5] 马鸣,魏思思,武一鹏,等. Mda-7/IL-24与C-myb在Burkitt淋巴瘤中的表达及其相关性研究[J]. 免疫学杂志,2017,33(8):691-696.
[6] 张之南,沈涕. 血液病诊断及疗效标准[M]. 3版. 北京:科学出版社,2007:157-163.
[7] XU S L,OSHIMA T,IMADA T,et al. Stabilization of MDA-7/IL-24 for colon cancer therapy[J]. Cancer Lett,2013(2),335:421-430.
[8] DONG C Y,ZHANG F,DUAN Y J,et al. Mda-7/IL-24 inhibits the proliferation of hematopoietic malignancies in vitro and in vivo[J]. Exp Hematol,2008,36(8):938-946.
[9] 姚兴荣,马晓彤,杨滨霞,等. Mda-7/IL-24和IL-24 delE5诱导急性髓系白血病细胞向单核细胞分化[J]. 中国肿瘤生物治疗杂志,2011,18(3):244-250.
[10] 马鸣,杨兴肖,王雪晓,等. Mda-7/IL-24对B细胞淋巴瘤化疗敏感性的影响[J]. 免疫学杂志,2016,32(2):187-194.
[11] CHAN Y H,CHIANG M F,TSAI Y C,et al. Absence of the transcriptional repressor blimp-1 in hematopoietic lineages reveals its role in dendritic cell homeostatic development and function[J]. J Immunol,2009,183(11):7039-7046.
[12] PARK Y S,KANG J W,LEE D H,et al. Interleukin-32α downregulates the activity of the B-cell CLL/lymphoma 6 protein by inhibiting protein kinase Cε-dependent SUMO-2 modification[J]. Oncotarget,2014,5(18):8765-8777.
[13] ZHENG T,CHEN L,NOH A L,et al. Cetylpyridinium chloride inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast formation[J]. Biol Pharm Bull,2013,36(4):509-514.
[14] ALTIERI P,SPALLAROSSA P,BARISIONE C,et al. Inhibition of doxorubicin-Induced senescence by PPARδ activation agonists in cardiac muscle cells:cooperation between PPARδ and Bcl6[J]. PLoS One,2012,7(9):e46126.
[15] 马鸣,杨兴肖,赵连梅,等. MDA-7/IL-24对Burkitt淋巴瘤细胞的诱导分化作用[J]. 中国肿瘤生物治疗杂志,2017,24(8):773-781.

Mda-7/IL-24和C-myb在弥漫大B细胞淋巴瘤中的表达及其临床意义

Clinical significance of Mda-7/IL-24 and C-myb expression in diffuse large B-cell lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	孙全武, 杜小平, 郝杰, 时荣, 刘波, 黄海云. 伴病理性乳头溢液的乳腺癌患者癌组织整合素β1的表达及意义[J]. 癌变·畸变·突变, 2019, 31(5): 368-372.
[2]	马鸣, 焦文静, 王延海, 颜晰, 张超, 张金艳. 弥漫大B细胞淋巴瘤患者血清IL-24及IL-6浓度检测的临床意义[J]. 癌变·畸变·突变, 2019, 31(3): 227-230.